Alexion's Soliris receives marketing approval in Japan Alexion Pharmaceuticals announced that the Ministry of Health, Labour and Welfare in Japan has approved the use of Soliris for the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome, a life-threatening ultra-rare disorder. Soliris is already approved in Japan for paroxysmal nocturnal hemoglobinuria, another severe and ultra-rare disease. Alexion expects that initial patients with aHUS in Japan will commence treatment with Soliris during Q4.
News For ALXN From The Last 14 Days
Check below for free stories on ALXN the last two weeks.